[1] SINGER M, DEUTSCHMAN CS, SEYMOUR CW, et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA, 2016, 315(8):801.
[2] DOIK.Role of kidney injury in sepsis[J].J Intensive Care, 2016, 4(1):17.
[3] 中国医师协会急诊医师分会, 中国研究型医院学会休克与脓毒症专业委员会.中国脓毒症/脓毒性休克急诊治疗指南(2018)[J].中国急救医学, 2018, 38(9):741.
[4] RHODES A, EVANS LE, ALHAZZANI W, et al.Surviving sepsis campaign:international guidelines for management of sepsis and septic shock:2016[J].Intensive Care Med, 2017, 43(3):304.
[5] BARTOLETTI M, ANTONELLI M, BRUNO BLASI FA, et al.Procalcitonin-guided antibiotic therapy:an expert consensus[J].Clin Chem Lab Med, 2018, 56(8):1223.
[6] PETERS E, ANTONELLI M, WITTEBOLE X, et al.A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission:results from TheIntensive Care Over Nations audit[J].Crit Care, 2018, 22(1):188.
[7] AMOUR J, BIRENBAUM A, LANGERON O, et al.Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery[J].Crit Care Med, 2008, 36(4):1147.
[8] HONORÉPM, DE BELS D, SPAPEN HD.An update on membranes and cartridges for extracorporeal blood purification in sepsis and septic shock[J].Curr Opin Crit Care, 2018, 24(6):463.
[9] 降钙素原急诊临床应用专家共识组.降钙素原(PCT)急诊临床应用的专家共识[J].中华急诊医学杂志, 2012, 21(9):944.
[10] VINCENT JL, MORENO R, TAKALA J, et al.The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure[J].Intensive Care Med, 1996, 22(7):707.
[11] KHWAJA A.KDIGO clnical ipractice guidelines for acute kidney injury[J].Nephron Clin Pract, 2012, 120(4):c179.
[12] JJV MM, PARFREY PS, AL E.KDIGO Clinical practice guideline for anemia in Chronic Kidney Disease[J].Kidney International Supplements, 2012, 2(4):279.
[13] VIJAYAN A L, VANIMAYA, RAVINDRAN S, et al.Procalcitonin:a promising diagnostic marker for sepsis and antibiotic therapy[J].J Intensive Care, 2017, 5(1):51.
[14] ENGUIXARMADA A, ESCOBARCONESA R, LA TORRE AG, et al.Usefulness of several biomarkers in the management of septic patients:C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin.[J].Clin Chem Lab Med, 2016, 54(1):163.
[15] CALDINI A, CHELAZZI C, TERRENI A, et al.Is procalcitonin a reliable marker of sepsis in critically ill septic patients undergoing continuous veno-venous hemodiafiltration with "high cut-off" membranes (HCO-CVVHDF)?[J].Clin Chem Lab Med, 2013, 51(11):e261.
[16] MAT NOR MB, MD RALIB A.Procalcitonin clearance for early prediction of survival in critically ill patients with severe sepsis[J].Crit Care Res Pract, 2014, 2014:819.
[17] RYU JA, YANG JH, LEE D, et al.Clinical usefulness of procalcitonin and c-reactive protein as outcome predictors in critically ill patients with severe sepsis and septic shock[J].PLoS One, 2015, 10(9):e138.
[18] DE AZEVEDO, JOSÉ RA, TORRESO JM, et al.Prognostic evaluation of severe sepsis and septic shock:procalcitonin clearance vs delta Sequential organ failure assessment[J].J Crit Care, 2015, 30(1):219.e9.
[19] RUIZ-RODRÍGUEZ JC, CABALLERO J, RUIZ-SANMARTIN A, et al.Usefulness of procalcitonin clearance as a prognostic biomarker in septic shock.A prospective pilot study[J].Med Intensiva, 2012, 36(7):475.
[20] KADE G, LITERACKI S, RZESZOTARSKA A, et al.Removal of procalcitonin and selected cytokines during continuous veno-venous hemodialysis using high cutoff hemofilters in patients with sepsis and acute kidney injury[J].Blood Purif, 2018, 46(2):153.